- Home
- HMY vs LEGN Comparison
HMY vs LEGN Comparison
Compare HMY & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- LEGN
- Stock Information
- Founded
- HMY 1950
- LEGN 2014
- Country
- HMY South Africa
- LEGN United States
- Employees
- HMY N/A
- LEGN N/A
- Industry
- HMY Precious Metals
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- HMY Basic Materials
- LEGN Health Care
- Exchange
- HMY Nasdaq
- LEGN Nasdaq
- Market Cap
- HMY 7.5B
- LEGN 7.0B
- IPO Year
- HMY N/A
- LEGN 2020
- Fundamental
- Price
- HMY $14.07
- LEGN $35.06
- Analyst Decision
- HMY Sell
- LEGN Strong Buy
- Analyst Count
- HMY 3
- LEGN 13
- Target Price
- HMY $6.60
- LEGN $79.17
- AVG Volume (30 Days)
- HMY 6.8M
- LEGN 1.1M
- Earning Date
- HMY 01-01-0001
- LEGN 03-11-2025
- Dividend Yield
- HMY 1.08%
- LEGN N/A
- EPS Growth
- HMY 16.30
- LEGN N/A
- EPS
- HMY 0.88
- LEGN N/A
- Revenue
- HMY $3,553,951,394.00
- LEGN $627,241,000.00
- Revenue This Year
- HMY $17.62
- LEGN $66.60
- Revenue Next Year
- HMY $7.93
- LEGN $49.28
- P/E Ratio
- HMY $15.52
- LEGN N/A
- Revenue Growth
- HMY 16.84
- LEGN 119.97
- 52 Week Low
- HMY $7.97
- LEGN $30.17
- 52 Week High
- HMY $14.38
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- HMY 75.58
- LEGN 44.07
- Support Level
- HMY $12.50
- LEGN $34.00
- Resistance Level
- HMY $13.12
- LEGN $36.20
- Average True Range (ATR)
- HMY 0.40
- LEGN 1.52
- MACD
- HMY 0.12
- LEGN -0.25
- Stochastic Oscillator
- HMY 88.38
- LEGN 25.18
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.